

28 January 2026

## Quarterly Activities Report Period Ending 31 December 2025

### Key Highlights

- Record **\$17.2 million** quarterly revenue, a **112% increase** on Q2 FY25 and a **21% increase** on Q1 FY26
- Record **\$18.4 million** quarterly **Cash Receipts**, representing a **149% increase** on Q2 FY25 and a 43% increase on Q1 FY26.
- \$2.5 million positive Q2 cash flow from operating activities
- Completed dual listing on the Frankfurt Stock Exchange (ticker: **PR8.F**) on 13 October 2025, enhancing liquidity and access for European investors
- Executed exclusive import, manufacture, and supply agreement with Curaleaf International for the Que Medical Inhalation Device in Australia
- Released first Australian-made GMP MDMA capsules for supply to clinical trials in Victoria and authorised prescribers in Queensland, fulfilling orders for over 400 patient doses
- Ranked in the Deloitte Technology Fast 50 Australia 2025 on 24 November 2025, recognising 452% revenue growth from FY22–FY24 in the Healthcare Technology / Life Sciences category
- Second shipment of Australian-manufactured GMP MDMA capsules to Victoria's Eastern Health, supporting a public health clinical trial for treatment-resistant PTSD co-occurring with borderline personality disorder
- Secured manufacturing and supply agreement with Remidose, positioning Bioxyne as a first mover in Costa Rica and Panama, with potential annual revenue exceeding A\$1 million following regulatory approvals
- Secured **£848,250 (approximately A\$1.6 million) in non-dilutive funding** from South of Scotland Enterprise to establish a new GMP manufacturing facility in the Scottish Borders
- Positive regulatory developments in key markets, including potential US rescheduling of cannabis to Schedule III, ongoing reforms in Germany, and the UK's medicinal cannabis framework
- **\$7.6 million** cash on hand at 31 December 2025

**Bioxyne Limited (ASX: BXN) ("Bioxyne" or "the Company"),** an Australian pharmaceutical company focused on the development and commercialisation of innovative medicines and active pharmaceutical ingredients, is pleased to report a strong Q2 FY26 trading performance.

Sustained growth in Breathe Life Sciences (BLS) Australia, with increasing demand for its cannabis portfolio, including flower, oils, vapes, pastilles, and the newly launched Que Medical Inhalation Device (QMID), drove the revenue results. International expansion contributed significantly, with additional invoicing from the German purchase orders (A\$2.9 million in Q2),



the Curaleaf partnership, and MDMA supplies. The psychedelics segment emerged as a growth driver with the MDMA releases and shipments.

Inventory increased to A\$11.5 million from \$6.1 million in Q1 FY26, with a further investment to meet scheduled demand in H2 CY26. In addition the Company has prepaid for product yet to be received. Trade receivables were managed effectively, increasing to A\$4 million (\$2.5 million at year end FY25), less than increase in revenue, achieved through improved payment terms and collections.


Capex during the quarter was \$0.7 million, primarily invested in infrastructure enhancements in Australia and initial planning for the UK facility.

**Chief Executive Officer Sam Watson commented:**

*"Q2 FY2026 has delivered another strong performance, with record quarterly revenue alongside positive operating cash flow. These results reflect the continued execution of our disciplined and scalable operating model. With accelerating demand across our diversified geographic footprint and a strong balance sheet supporting the strategic investments we have already made in manufacturing capacity and inventory, we remain firmly on track to deliver our FY2026 guidance of \$65–75 million in revenue and \$11.5–13.5 million in underlying EBITDA."*

**Revenue**

Group revenue grew by 21% to a record \$17.2 million for the quarter versus the previous quarter. This was attributable to outperformance from BLS Australia, with expanded manufacturing capacity driving growth in white-label and branded products. Early contributions from psychedelics, including MDMA supplies, added to the portfolio.






## Cash Receipts

The Company reported cash receipts of \$18.4 million during the quarter, representing a significant increase on both the prior corresponding period and the previous quarter.

Cash from operations was \$2.5 million in Q2 FY26, benefitting from increased operations and a research and development tax offset of \$1.1 million. The Company invested further in working capital in Q2 FY26 to meet the forecast demand in 2H FY2026.



## Operations

### Dual Listing on Frankfurt Stock Exchange

The Company successfully listed on the Frankfurt Stock Exchange (FSE) on 13 October 2025 trading under the ticker code PR8.F

The listing supports the Company's focus on Europe, with Germany the largest and fastest growing legal cannabis market in Europe projected to surpass €1 billion (A\$1.8 billion) in sales in 2026.

### Curaleaf Agreement

Bioxyne, via BLS, signed an exclusive agreement with Curaleaf International, a global leader in medicinal cannabis, granting BLS rights to import, manufacture and distribute Curaleaf's QMID in Australia. The QMID is the first EU CE-certified Class IIa medical device for use with liquid cannabis inhalants, distinguishing it from standard vapes by offering precise, consistent dosing for patients with conditions such as chronic pain or nausea. This adds a



recurring revenue stream from devices and replacement cartridges, with projected contributions supporting Bioxyne's FY26 financial guidance.

### **Remidose Agreement**

On 10 December 2025, Bioxyne entered into a manufacturing and supply agreement with Remidose, a Central American distributor focused on pharmaceutical products. Under the agreement, BLS will manufacture THC pastille products for supply into the emerging medicinal cannabis markets of Costa Rica and Panama. This positions Bioxyne as a first mover in these markets, where regulatory frameworks for medicinal cannabis are rapidly evolving. Upon full regulatory approvals, expected in early 2026, the agreement has the potential to generate annual revenue exceeding A\$1 million.

### **Australia's First Domestic Supply of Manufactured GMP-compliant MDMA capsules**

Breathe Life Sciences (BLS), fulfilled two purchase orders for Australia's first domestically manufactured GMP-compliant MDMA capsules – an investigational medicine for treatment-resistant PTSD via MDMA-assisted therapy.

These high-quality capsules, meeting Australian and international standards, supplied over 400 patient doses to clinical trials in Victoria and authorised prescribers in Queensland. A second shipment supported a public health trial at Eastern Health's Box Hill Hospital, exploring MDMA-assisted psychotherapy for co-occurring PTSD (or complex PTSD) and borderline personality disorder – a treatment-resistant dual diagnosis.

This milestone establishes BLS as Australia's pioneering supplier of pharmaceutical-grade MDMA, reducing import reliance amid rising demand. With ~12% of Australians experiencing PTSD in their lifetime and the global psychedelic drugs market projected to reach ~AUD 14 billion by 2032, Bioxyne is positioned at the forefront of innovative mental health solutions.

### **Funding to fit-out and establish UK medicinal cannabis manufacturing and distribution facility**

Through its subsidiary Breathe Life Sciences UK Ltd (BLSUK), Bioxyne secured £848,250 (approximately A\$1.6 million) in funding from South of Scotland Enterprise to establish a new GMP manufacturing facility in the Scottish Borders.

BLSUK has secured a site of equivalent size to its Australian facility and recently made two key appointments, with the new Head of Production and Head of Quality commencing in January 2026.

Site fit-out and applications for MHRA and Home Office licences will be completed in 2026, positioning BLSUK as a significant provider of manufacturing and distribution services to the UK medicinal cannabis market and a key regional employer in South of Scotland.



## **Deloitte Technology Fast 50 Australia 2025 Awards**

Bioxyne was recognised in the Deloitte Technology Fast 50 Australia 2025 awards, announced on 20 November 2025. The ranking celebrates the 50 fastest-growing technology companies based on verified revenue growth over three years (FY22–FY24), with Bioxyne achieving 452% growth in the Healthcare Technology / Life Sciences category.

## **Annual General Meeting**

The Company's Annual General Meeting was held on 26 November 2025, with all resolutions passed on a poll, demonstrating strong shareholder support.

## **Management Additions**

During the quarter, Bioxyne appointed Paul Mitchell as CFO of its major operating subsidiary Breathe Life Sciences (BLS), bolstering financial oversight during a period of rapid growth.

## **Regulatory Developments**

The quarter saw significant regulatory progress across key markets that supports the Company's strategic positioning.

In Germany, ongoing positive developments continue to benefit Bioxyne's Adrex partnership, with patient access improvements. Germany's CanG reforms de-narcotised medicinal cannabis in 2024. Anticipated changes to German telemedicine and mail order dispensing rules in 2026 are positive for Bioxyne with its strong local access and distribution to pharmacies across Germany.

In the United States, the rescheduling of cannabis to Schedule III continues to open opportunities for research and market access, aligning with the Company's probiotics distribution strategy. Late in the quarter, a US Presidential executive order advanced this rescheduling process to Schedule III, with implementation processes expected to continue into 2026.

In the UK, the 2018 regulatory framework was subject to a 2025 advisory council on the misuse of drugs review to improve patient access to cannabis based products for medicinal use (CBPMs). This review comes amid a 262% rise in prescriptions since 2022, demonstrating growing market acceptance and patient demand.

These developments align with Bioxyne's strengths as a licensed manufacturer, wholesaler, acting as a gateway to market access.

## **Financials**

Capex of \$0.7 million during the quarter was primarily invested in infrastructure enhancements in Australia and initial planning for the UK facility.

Working capital was optimised, with a focus on receivables collection and supplier terms as the business scales up.



The Company paid directors fees and salaries in the amount of \$181,000 for the Quarter.

Cash balance at 31 December 2025 was \$7.6 million.

Unaudited management accounts remain in line with the required run-rate to meet or exceed stated guidance of **\$11.5 million to \$13.5 million Underlying EBITDA in FY26.**

## **Outlook**

The Company is focussed on:

- Executing on international expansion, including the UK GMP facility fit out and Central American market entry
- Improving operational efficiencies through ERP enhancements and supply chain optimisation
- Gaining EU GMP certification in Europe, scaling UK and European operations
- Expanding medicinal cannabis and psychedelics sales in core markets with local partners

## **Approved by the Board of Bioxyne Limited for release to the ASX.**

For further information, please contact:

Bioxyne Limited

Sam Watson

Chief Executive Officer

[info@bioxyne.com](mailto:info@bioxyne.com)

NWR Communications

Melissa Tempura

Media & Investor Relations

[melissa@nwrcommunications.com.au](mailto:melissa@nwrcommunications.com.au)

## **About Bioxyne Limited**

Bioxyne Limited is an Australian pharmaceutical company focused on the development and commercialisation of innovative medicines and active pharmaceutical ingredients. Through its subsidiary, Breathe Life Sciences, Bioxyne is expanding into the production of psychedelic compounds for therapeutic use.

## **About Breathe Life Sciences**

Breathe Life Sciences (“BLS”) is a wholly owned subsidiary of Bioxyne Ltd (BXN:ASX) and GMP-licensed manufacturer, wholesaler, importer and exporter of controlled substances (S3, S4, S8, S9), including medicinal cannabis, Psilocybin, and MDMA.

BLS was founded in 2018 and has quickly expanded into a multi-national business focused on alternative therapeutics and investigational medicines. The company’s corporate head office is in Sydney, with operations and licensed manufacturing, warehousing,



import/export, sales and distribution centres in Queensland (Australia), Nagoya (Japan), Manchester (UK), and Prague (Czechia).

The BLS business model is focused on manufacturing final dose form medicines, sales and distribution. BLS sources raw materials and API from suppliers in 5 continents and is the Australian market leading manufacturer of therapeutic goods including cannabis, MDMA, and Psilocybin.

Outside of Australia the BLS Group operates in pharmaceuticals, medical cannabis, consumer health products, and novel foods (CBD). In the UK, Europe and Japan, the Company engages in the following activities:

- a. Owner of Dr Watson® brand in the UK, Japan, Australia and New Zealand. Internationally recognized for its cannabis-based food supplements, health products, and prescription-only cannabis medicines.
- b. Contract drug manufacturing and white label manufacturing of scheduled medicines, therapeutic goods, medical devices, consumer health products, and active pharmaceutical ingredients. BLS manufactures over 200 of Australia's medicinal cannabis brands.
- c. Import, export, and wholesale of active pharmaceutical ingredients, starting materials, patient-ready medicinal products, and/or consumer health products in Australia, Japan, UK, USA and Europe
- d. Research and development of novel medicines.
- e. Direct sales via online and wholesale of BLS-owned consumer brands, such as Dr Watson®

Corporate: [bioxyne.com](https://www.bioxyne.com)

Australia: [bls.com.au](https://www.bls.com.au)

International: [breathelifesciences.com](https://www.breathelifesciences.com)

United Kingdom: [drwatsoncbd.com](https://www.drwatsoncbd.com)

## Appendix 4C

### Quarterly cash flow report for entities subject to Listing Rule 4.7B

**Name of entity**

Bioxyne Limited

**ABN**

97 084 464 193

**Quarter ended ("current quarter")**

31 December 2025

<b>Consolidated statement of cash flows</b>	<b>Current quarter \$A'000</b>	<b>Year to date (6 months) \$A'000</b>
<b>1. Cash flows from operating activities</b>		
1.1 Receipts from customers	18,358	31,307
1.2 Payments for		
(a) research and development	(51)	(91)
(b) product manufacturing and operating costs	(15,245)	(30,364)
(c) advertising and marketing	(68)	(131)
(d) leased assets	(27)	(54)
(e) staff costs (including directors fees)	(274)	(821)
(f) administration and corporate costs	(1,293)	(2,539)
1.3 Dividends received (see note 3)		
1.4 Interest received	47	79
1.5 Interest and other costs of finance paid	(19)	(19)
1.6 Income taxes paid		
1.7 Government grants and tax incentives	1,059	1,059
1.8 Other (provide details if material)		
<b>1.9 Net cash from / (used in) operating activities</b>	<b>2,487</b>	<b>(1,574)</b>
<b>2. Cash flows from investing activities</b>		
2.1 Payments to acquire:		
(a) entities		
(b) businesses		
(c) property, plant and equipment	(731)	(975)
(d) investments		
(e) intellectual property		
(f) other non-current assets		

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (6 months) \$A'000
2.2	Proceeds from disposal of:		
	(a) entities		
	(b) businesses		
	(c) property, plant and equipment		
	(d) investments		
	(e) intellectual property		
	(f) other non-current assets		
2.3	Cash flows from loans to other entities		
2.4	Dividends received (see note 3)		
2.5	Other (provide details if material) cash on acquisition of subsidiary		
<b>2.6</b>	<b>Net cash from / (used in) investing activities</b>	<b>(731)</b>	<b>(976)</b>
<b>3.</b>	<b>Cash flows from financing activities</b>		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	110	110
3.2	Proceeds from issue of convertible debt securities		
3.3	Proceeds from exercise of options		
3.4	Transaction costs related to issues of equity securities or convertible debt securities		
3.5	Proceeds from borrowings (lease)/other	1,291	2,504
3.6	Loan to third party		
3.7	Repayment of borrowings	(121)	(121)
3.8	Dividends paid		
3.9	Other		(15)
<b>3.10</b>	<b>Net cash from / (used in) financing activities</b>	<b>1,280</b>	<b>2,478</b>
<b>4.</b>	<b>Net increase / (decrease) in cash and cash equivalents for the period</b>		
4.1	Cash and cash equivalents at beginning of period	4,543	7,668
4.2	Net cash from / (used in) operating activities (item 1.9 above)	2,487	(1,574)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(731)	(976)

<b>Consolidated statement of cash flows</b>		<b>Current quarter \$A'000</b>	<b>Year to date (6 months) \$A'000</b>
4.4	Net cash from / (used in) financing activities (item 3.10 above)	1,280	2,478
4.5	Effect of movement in exchange rates on cash held	23	6
<b>4.6</b>	<b>Cash and cash equivalents at end of period</b>	<b>7,602</b>	<b>7,602</b>

<b>5.</b>	<b>Reconciliation of cash and cash equivalents</b> at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	<b>Current quarter \$A'000</b>	<b>Previous quarter \$A'000</b>
5.1	Bank balances	7,602	4,543
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
<b>5.5</b>	<b>Cash and cash equivalents at end of quarter (should equal item 4.6 above)</b>	<b>7,602</b>	<b>4,543</b>

**6. Payments to related parties of the entity and their associates**

6.1 Aggregate amount of payments to related parties and their associates included in item 1

6.2 Aggregate amount of payments to related parties and their associates included in item 2

<b>Current quarter \$A'000</b>
------------------------------------

181
-----

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments

The amount in item 6.1 represents director's fees and salaries.

**7. Financing facilities**

*Note: the term "facility" includes all forms of financing arrangements available to the entity.*

*Add notes as necessary for an understanding of the sources of finance available to the entity.*

	<b>Total facility amount at quarter end \$A'000</b>	<b>Amount drawn at quarter end \$A'000</b>
7.1 Loan facilities	(1) 744 (2) 1,005	744 1,005
7.2 Credit standby arrangements		
7.3 Other (please specify)		
<b>7.4 Total financing facilities</b>	<b>1,749</b>	<b>1,749</b>

7.5 **Unused financing facilities available at quarter end** Nil

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

- (1) NAB, term to 30 June 2028, unsecured, interest 8%  
(2) South of Scotland Enterprise, 60 months to December 2030, unsecured, interest 9.5%

<b>8. Estimated cash available for future operating activities</b>	<b>\$A'000</b>
8.1 Net cash from / (used in) operating activities (Item 1.9)	2,487
8.2 Cash and cash equivalents at quarter end (Item 4.6)	7,602
8.3 Unused finance facilities available at quarter end (Item 7.5)	-
8.4 Total available funding (Item 8.2 + Item 8.3)	7,602
<b>8.5 Estimated quarters of funding available (Item 8.4 divided by Item 8.1)</b>	<b>N/A</b>

*Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.*

8.6 If Item 8.5 is less than 2 quarters, please provide answers to the following questions:

1. Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

2. Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

3. Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

**Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.**

## Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 28 January 2026.....

Authorised by: ..The Board.....  
(Name of body or officer authorising release – see note 4)

## Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.